Recro

Evolus & Urovant: Similar Strategies, Opposite Reactions to Positive Catalysts
Gallery
Evolus & Urovant: Similar Strategies, Opposite Reactions to Positive Catalysts

Bill Langbein, Case Study, Education, Healthcare, Insights, Pharmaceutical & Biotechnology

Evolus & Urovant: Similar Strategies, Opposite Reactions to Positive Catalysts

By Bill Langbein|2019-03-25T11:45:49-04:00March 25th, 2019|Categories: Bill Langbein, Case Study, Education, Healthcare, Insights, Pharmaceutical & Biotechnology|Tags: biotech, Botox, Recro, REPH, SanaCurrents|

One of the strongest performing biopharmaceutical stocks this year is [...]

0

Recro To Consider Dispute Resolution With FDA After Complete Response Letter
Gallery
Recro To Consider Dispute Resolution With FDA After Complete Response Letter

Bill Langbein, Insights, SanaCurrents

Recro To Consider Dispute Resolution With FDA After Complete Response Letter

By Bill Langbein|2019-03-25T11:40:52-04:00March 24th, 2019|Categories: Bill Langbein, Insights, SanaCurrents|Tags: Complete Response Letter, CRL, Recro, REPH|

Shares of Recro Pharma, Inc. (NASDAQ:REPH) likely will fall in [...]

0